Clinical Practice Guideline for Blood-based Circulating Tumor DNA Assays

다국어 초록 (Multilingual Abstract)

Circulating tumor DNA (ctDNA) has emerged as a promising tool for various clinical applications, including early diagnosis, therapeutic target identification, treatment response monitoring, prognosis evaluation, and minimal residual disease detection. Consequently, ctDNA assays have been incorporated into clinical practice. In this review, we offer an in-depth exploration of the clinical implementation of ctDNA assays. Notably, we examined existing evidence related to pre-analytical procedures, analytical components in current technologies, and result interpretation and reporting processes. The primary objective of this guidelines is to provide recommendations for the clinical utilization of ctDNA assays.

참고문헌 (Reference)

1 Willis J, "Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel" 25 : 7035-7045, 2019

2 Crysup B, "Using unique molecular identifiers to improve allele calling in low-template mixtures" 63 : 102807-, 2023

3 Jacobs MT, "Use of low-frequency driver mutations detected by cell-free circulating tumor DNA to guide targeted therapy in non-small-cell lung cancer : a multicenter case series" 2 : 1-10, 2018

4 Acuna-Hidalgo R, "Ultra-sensitive sequencing identifies high prevalence of clonal hematopoiesis-associated mutations throughout adult life" 101 : 50-64, 2017

5 Jamal-Hanjani M, "Tracking the evolution of non-small-cell lung cancer" 376 : 2109-2121, 2017

6 Bruehl FK, "Tiered somatic variant classification adoption has increased worldwide with some practice differences based on location and institutional setting" 146 : 822-832, 2022

7 Ponti G, "The value of fluorimetry(Qubit)and spectrophotometry(NanoDrop)in the quantification of cell-free DNA(cfDNA)in malignant melanoma and prostate cancer patients" 479 : 14-19, 2018

8 Henriksen TV, "The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA" 14 : 1670-1679, 2020

9 Parpart-Li S, "The effect of preservative and temperature on the analysis of circulating tumor DNA" 23 : 2471-2477, 2017

10 Li Z, "The cornerstone of integrating circulating tumor DNA into cancer management" 1871 : 1-11, 2019

11 Tomczak K, "The Cancer Genome Atlas(TCGA) : an immeasurable source of knowledge" 19 : A68-A77, 2015

12 Horak P, "Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)" 24 : 986-998, 2022

13 Richards S, "Standards and guidelines for the interpretation of sequence variants : a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology" 17 : 405-424, 2015

14 Li MM, "Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists" 19 : 4-23, 2017

15 Chakravarty D, "Somatic genomic testing in patients with metastatic or advanced cancer : ASCO provisional clinical opinion" 40 : 1231-1258, 2022

16 Sequence Variant Working Group, "Sequence Variant Interpretation"

17 Koessler T, "Reliability of liquid biopsy analysis : an inter-laboratory comparison of circulating tumor DNA extraction and sequencing with different platforms" 100 : 1475-1484, 2020

18 Heitzer E, "Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer" 7 : 100399-, 2022

19 Wang Q, "Real-time PCR evaluation of cell-free DNA subjected to various storage and shipping conditions" 14 : 12797-12804, 2015

20 Meddeb R, "Quantifying circulating cell-free DNA in humans" 9 : 5220-, 2019

21 van Ginkel JH, "Preanalytical blood sample workup for cell-free DNA analysis using Droplet Digital PCR for future molecular cancer diagnostics" 6 : 2297-2307, 2017

22 Li MM, "Points to consider for reporting of germline variation in patients undergoing tumor testing : a statement of the American College of Medical Genetics and Genomics(ACMG)" 22 : 1142-1148, 2020

23 Abbosh C, "Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution" 545 : 446-451, 2017

24 Medina Diaz I, "Performance of Streck cfDNA blood collection tubes for liquid biopsy testing" 11 : e0166354-, 2016

25 "Performance evaluation guidelines for next generation sequencing in vitro diagnostic medical devices" Ministry of Food and Drug Safety

26 ICGC/TCGA Pan-Cancer of Whole Genomes Consortium, "Pan-cancer analysis of whole genomes" 578 : 82-93, 2020

27 Song Ho Hyun ; Park Hye Ran ; Cho Doohwan ; Bang Hae In ; 오혁진 ; Kim Jieun, "Optimization of a protocol for isolating cell-free DNA from cerebrospinal fluid" 2023

28 Chakravarty D, "OncoKB : a precision oncology knowledge base" 2017 : PO.17.00011-, 2017

29 Chakravarty D, "OncoKB : a precision oncology knowledge base" 2017 : 2017

30 "On-site inspection evaluation checklist"

31 Georgiadis A, "Noninvasive detection of microsatellite instability and high tumor mutation burden in cancer patients treated with PD-1 blockade" 25 : 7024-7034, 2019

32 Singh RR, "Next-generation sequencing in high-sensitive detection of mutations in tumors: challenges, advances, and applications" 22 : 994-1007, 2020

33 Parikh AR, "Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer" 27 : 5586-5594, 2021

34 Qiu P, "Measuring tumor mutational burden(TMB)in plasma from mCRPC patients using two commercial NGS assays" 9 : 114-, 2019

35 Kim SY, "Manual for guideline adaptation ver 2.0" National Evidence-based Healthcare Collaborating Agency 2011

36 Lee JS, "Liquid biopsy in pancreatic ductal adenocarcinoma : current status of circulating tumor cells and circulating tumor DNA" 13 : 1623-1650, 2019

37 Kloten V, "Liquid biopsy in colon cancer : comparison of different circulating DNA extraction systems following absolute quantification of KRAS mutations using Intplex allele-specific PCR" 8 : 86253-86263, 2017

38 "Laboratory accreditation program checklist, molecular diagnostic test"

39 Zheng Z, "Intratumor heterogeneity : A new perspective on colorectal cancer research" 9 : 7637-7645, 2020

40 Newman AM, "Integrated digital error suppression for improved detection of circulating tumor DNA" 34 : 547-555, 2016

41 Stout LA, "Identification of germline cancer predisposition variants during clinical ctDNA testing" 11 : 13624-, 2021

42 Bourbon E, "How to obtain a high quality ctDNA in lymphoma patients : preanalytical tips and tricks" 14 : 617-, 2021

43 Wang TT, "High efficiency error suppression for accurate detection of low-frequency variants" 47 : e87-, 2019

44 Jennings LJ, "Guidelines for validation of next-generation sequencing-based oncology panels : A joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists" 19 : 341-365, 2017

45 Meddeb R, "Guidelines for the preanalytical conditions for analyzing circulating cell-free DNA" 65 : 623-633, 2019

46 Cristiano S, "Genome-wide cell-free DNA fragmentation in patients with cancer" 570 : 385-389, 2019

47 Godsey JH, "Generic protocols for the analytical validation of next-generation sequencing-based ctDNA assays : a joint consensus recommendation of the BloodPAC’s Analytical Variables Working Group" 66 : 1156-1166, 2020

48 Trigg RM, "Factors that influence quality and yield of circulating-free DNA : a systematic review of the methodology literature" 4 : e00699-, 2018

49 Marcus L, "FDA approval summary : pembrolizumab for the treatment of tumor mutational burden-high solid tumors" 27 : 4685-4689, 2021

50 Stockley T, "Evidence-based best practices for EGFR T790M testing in lung cancer in Canada" 25 : 163-169, 2018

51 Diefenbach RJ, "Evaluation of commercial kits for purification of circulating free DNA" 228-9 : 21-27, 2018

52 Deveson IW, "Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology" 39 : 1115-1128, 2021

53 Mouliere F, "Enhanced detection of circulating tumor DNA by fragment size analysis" 10 : eaat4921-, 2018

54 Sozzi G, "Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays" 97 : 1848-1850, 2005

55 Chan KC, "Effects of preanalytical factors on the molecular size of cell-free DNA in blood" 51 : 781-784, 2005

56 Chiu RW, "Effects of blood-processing protocols on fetal and total DNA quantification in maternal plasma" 47 : 1607-1613, 2001

57 Abbosh C, "Early stage NSCLC – challenges to implementing ctDNA-based screening and MRD detection" 15 : 577-586, 2018

58 Pascual J, "ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer : a report from the ESMO Precision Medicine Working Group" 33 : 750-768, 2022

59 Barra GB, "EDTA-mediated inhibition of DNases protects circulating cell-free DNA from ex vivo degradation in blood samples" 48 : 976-981, 2015

60 Jain M, "Direct comparison of QIAamp DSP Virus Kit and QIAamp Circulating Nucleic Acid Kit regarding cell-free fetal DNA isolation from maternal peripheral blood" 43 : 13-19, 2019

61 Schmitt MW, "Detection of ultra-rare mutations by next-generation sequencing" 109 : 14508-14513, 2012

62 Sundaresan TK, "Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses" 22 : 1103-1110, 2016

63 Kinde I, "Detection and quantification of rare mutations with massively parallel sequencing" 108 : 9530-9535, 2011

64 Moding EJ, "Detecting liquid remnants of solid tumors : circulating tumor DNA minimal residual disease" 11 : 2968-2986, 2021

65 Heitzer E, "Current and future perspectives of liquid biopsies in genomics-driven oncology" 20 : 71-88, 2019

66 조선미 ; Lee Hye Sun ; Jeon Soyoung ; Kim Yoonjung ; Kong Sun-Young ; Lee Jin Kyung ; Lee Kyung-A, "Cost-effectiveness analysis of three diagnostic strategies for the detection of EGFR mutation in advanced non-small cell lung cancer" 43 : 605-613, 2023

67 Bos MK, "Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA" 15 : 57-66, 2021

68 Bronkhorst AJ, "Comparison of methods for the isolation of cell-free DNA from cell culture supernatant" 42 : 1010428320916314-, 2020

69 Pérez-Barrios C, "Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients : impact on biomarker testing" 5 : 665-672, 2016

70 Morgan SR, "Comparison of KRAS mutation assessment in tumor DNA and circulating free DNA in plasma and serum samples" 5 : 15-22, 2012

71 Genovese G, "Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence" 371 : 2477-2487, 2014

72 Shin Saeam ; Woo Hye In ; 김종원 ; M.D. Yoonjung Kim ; Lee Kyung-A, "Clinical practice guidelines for pre-analytical procedures of plasma epidermal growth factor receptor variant testing" 42 : 141-149, 2022

73 Larson KL, "Clinical outcomes of molecular tumor boards : a systematic review" 5 : 2021

74 Mouliere F, "Circulating tumor-derived DNA is shorter than somatic DNA in plasma" 112 : 3178-3179, 2015

75 Ignatiadis M, "Circulating tumor cells and circulating tumor DNA : challenges and opportunities on the path to clinical utility" 21 : 4786-4800, 2015

76 Merker JD, "Circulating tumor DNA analysis in patients with cancer : American Society of Clinical Oncology and College of American Pathologists joint review" 36 : 1631-1641, 2018

77 Azad TD, "Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer" 158 : 494-505, 2020

78 Kamat AA, "Circulating cell-free DNA : a novel biomarker for response to therapy in ovarian carcinoma" 5 : 1369-1374, 2006

79 El Messaoudi S, "Circulating cell free DNA : preanalytical considerations" 424 : 222-230, 2013

80 Jung M, "Changes in concentration of DNA in serum and plasma during storage of blood samples" 49 : 1028-1029, 2003

81 Helman E, "Cell-free DNA next-generation sequencing prediction of response and resistance to third-generation EGFR inhibitor" 19 : 518-530, 2018

82 Gandara DR, "Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab" 24 : 1441-1448, 2018

83 Clarke CA, "BLOODPAC : collaborating to chart a path towards blood-based screening for early cancer detection" 16 : 5-9, 2023

84 Ma X, "Analysis of error profiles in deep next-generation sequencing data" 20 : 50-, 2019

85 Pécuchet N, "Analysis of base-position error rate of next-generation sequencing to detect tumor mutations in circulating DNA" 62 : 1492-1503, 2016

86 Miller DT, "ACMG SF v3. 1 list for reporting of secondary findings in clinical exome and genome sequencing : A policy statement of the American College of Medical Genetics and Genomics(ACMG)" 24 : 1407-1414, 2022

87 Baker A, "A review of grading systems for evidence-based guidelines produced by medical specialties" 10 : 358-363, 2010

88 Wagner AH, "A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer" 52 : 448-457, 2020

89 Mateo J, "A framework to rank genomic alterations as targets for cancer precision medicine : the ESMO Scale for Clinical Actionability of molecular Targets(ESCAT)" 29 : 1895-1902, 2018

90 Sorber L, "A comparison of cell-free DNA isolation kits : isolation and quantification of cell-free DNA in plasma" 19 : 162-168, 2017

91 The Korean Society of Radiology, "2020 Clinical imaging guidelines for justification of diagnostic imaging study by types of patients"